The BondBloxx CCC Rated USD High Yield Corp Bond ETF (XCCC) now presents an attractive entry point as CCC credit spreads have widened to their upper range. XCCC offers a 12.5% SEC yield with monthly payouts and diversification across sectors and issuers, reducing risk in the riskiest credit segment. Its low duration of 2.4 years makes it less sensitive to rising interest rates, improving its risk/reward profile compared to long-duration treasury bonds. Analysts recommend a small buy position in XCCC due to strong U.S. high-yield fundamentals and favorable compensation for credit risk.
The BondBloxx CCC Rated USD High Yield Corp Bond ETF (XCCC) offers a 12.5% SEC yield, providing a notable income opportunity. For readers following U.S. stocks on Pluang, here is the market snapshot as of Sep 15, 2026 21:57 WIB: out of 150 priced US stocks, 37 rose and 111 fell. Notable movers include SE (Sea Limited) at USD 102.70 down 5.50%, XPEV (Xpeng Inc - ADR) at USD 10.16 down 5.09%, and LI (Li Auto Inc) at USD 11.56 down 5.01%.
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...
